Literature DB >> 8190591

Kernicterus in premature infants: current prevalence and relationship to NICHD Phototherapy Study exchange criteria.

J F Watchko1, D Claassen.   

Abstract

OBJECTIVE: This study was undertaken to determine the current prevalence of kernicterus in premature neonates and to relate the occurrence of kernicterus to 1) the categorization of the infant as "at risk" by National Institute of Child Health and Human Development (NICHD) Phototherapy Study exchange transfusion criteria, and 2) the clinical management of the infant's hyperbilirubinemia.
DESIGN: Retrospective review of postmortem and clinical records.
SETTING: Magee-Womens Hospital, a University of Pittsburgh Medical Center affiliated hospital with approximately 10,000 deliveries per year and a Level III Neonatal Intensive Care Unit with about 1400 admissions annually.
SUBJECTS: All neonates autopsied between January 1, 1984 and June 30, 1993 who were < 34 weeks gestation and who lived at least 48 hours; a total of 81 infants.
RESULTS: Three infants had kernicterus resulting in a prevalence rate of 4%. These cases included: 1) a 33-week newborn with nonimmune hydrops and a peak bilirubin of 26 mg/dl; 2) a 25-week newborn with asphyxia, hyaline membrane disease, grade IV intraventricular hemorrhage, necrotizing enterocolitis, meconium peritonitis, sepsis, prolonged acidosis, and a peak bilirubin of 11.3 mg/dl; and 3) a 24-week newborn with asphyxia, hyaline membrane disease, grade III intraventricular hemorrhage, and a peak serum bilirubin of 18.5 mg/dl. Of the remaining 78 infants who did not have kernicterus, peak bilirubin ranged from 3.6 to 22.5 mg/dl and 56% had bilirubin levels greater than that suggested as a criterion for exchange transfusion by NICHD Phototherapy Study guidelines; yet all but three were managed with phototherapy alone.
CONCLUSIONS: We conclude that kernicterus is currently an uncommon event in preterm infants, even when bilirubin levels are allowed to rise above those previously thought to place the premature infant at risk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190591

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Jaundice in low birthweight infants: pathobiology and outcome.

Authors:  J F Watchko; M J Maisels
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

Review 2.  Kernicterus as a 'Never-Event': a newborn safety standard?

Authors:  Vinod K Bhutani
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

3.  Cloning and overexpression of rat kidney biliverdin IX alpha reductase as a fusion protein with glutathione S-transferase: stereochemistry of NADH oxidation and evidence that the presence of the glutathione S-transferase domain does not effect BVR-A activity.

Authors:  O Ennis; R Maytum; T J Mantle
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

4.  Hyperbilirubinemia diminishes respiratory drive in a rat pup model.

Authors:  Oded Mesner; Martha J Miller; Sabine C Iben; K C Prabha; Catherine A Mayer; Musa A Haxhiu; Richard J Martin
Journal:  Pediatr Res       Date:  2008-09       Impact factor: 3.756

Review 5.  Treatment of jaundice in low birthweight infants.

Authors:  M J Maisels; J F Watchko
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

6.  Amplitude of low-frequency fluctuation may be an early predictor of delayed motor development due to neonatal hyperbilirubinemia: a fMRI study.

Authors:  Kai Yan; Feifan Xiao; Yuwei Jiang; Chunmei Lu; Yong Zhang; Yanting Kong; Jian Zhou; Junbo Wang; Chengxiang Lin; Haowei Yang; Dajiang Zhang; Guoqiang Cheng; Zhongwei Qiao; Liping Wang; Qian Qin; Wenhao Zhou
Journal:  Transl Pediatr       Date:  2021-05

7.  Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia.

Authors:  Mattie F Wolf; Julie Childers; Keyaria D Gray; Caroline Chivily; Mike Glenn; Laila Jones; Mini Kpa; Taylor McMannen; Isaias Reyes; Kanecia O Zimmerman; Reese H Clark; Rachel G Greenberg
Journal:  J Perinatol       Date:  2020-03-09       Impact factor: 3.225

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.